The burden of high drug costs is something that everyone with health insurance coverage is facing, explained Leigh Purvis, director, Health Services Research, AARP Public Policy Institute.
The burden of high drug costs is something that everyone with health insurance coverage is facing, explained Leigh Purvis, director, Health Services Research, AARP Public Policy Institute.
Transcript
How does the burden of high prescription drug costs in Medicare have a broader impact than just on Medicare beneficiaries?
This problem is not unique to Medicare. This is something that everyone who has health insurance coverage is facing, and frankly, all Americans are facing. A message we always like to drive home when it comes to prescription drug costs is that it’s an issue that affects everyone. You’re either paying for them at the pharmacy counter, you’re paying for them as part of your premiums or part of your cost-sharing as someone with health coverage, or you’re paying for them through your taxes. Programs like Medicare and Medicaid are spending a lot of money of these products, and that eventually will translate into taxes, and ultimately can turn into either higher taxes or cuts to the programs that people rely on.
How does the drug cost burden facing the US elderly population compare with the elderly population in other, similar countries?
I think high prescription drug costs are a challenge globally, but I think they’re much more so in the United States. We face much higher cost-sharing, we have higher cost-related non-adherence. Just the nature of the health coverage system in the United States is much more fragmented. It makes it harder for them to drive bargains on prices that other countries are able to do just by virtue of the fact that they’re bargaining on the behalf of everyone.
Research Shows Prior Authorization Denials Delay Critical Immunology Care
May 10th 2024Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More